– age over 45 years for men and more than 65 years for women.
In the coming years, we plan to implement comprehensive pilot projects in a number of countries with high Life Expectancy Index 2018: Hong Kong (84,1), Japan (83,9), Italy (83,2), Singapore (83,2), Israel (82,7), Canada (82,5), South Korea (82,4), Norway (82,3), New Zealand (82,0), Costa Rica (80,0), Qatar (78,3).
One of the pilot projects of the GLI hold in Georgia. Why in Georgia? Perfect ecology, fresh air and widespread gardening provides an opportunity for exercise, nutritious food and sunlight.
The Georgians people have a positive outlook on life and close social support groups. They walk a lot, but they also take time for leisure, and maintain a positive attitude and sense of humor about life. They sleep 8 hours and their diet includes not only nutrient-rich foods like berries, vegetables and greens, but also water thatâs naturally high in calcium and magnesium.
The GLI focuses on innovation methods that can be rapidly translated into patient wellness (diet, physical activity, prevention of deseases, diagnostic, treatment) as well as projects that have long-term goals (pharmacological, regenerative, biotehnology).
The professionals at the Global Longevity Institute study your personal heath; and if they identify any signs in your organism which may result in illness, they offer an extensive range of treatments to make you as healthy as you can be.
– age over 45 years for men and more than 65 years for women.
– family history (heredity);
– lack of physical activity;
– malignant neoplastic diseases.
– unbalanced nutrition and insufficient potassium intake;
– infection and imbalance of microbiota.
– ecology and water;
– insufficiency of vitamin D;
– intake of excess amount of table salt.
– chronic diseases (liver diseases, diabetes, cardiovascular diseases, autoimmune and neurodegenerative diseases, nighttime apnea, kidney diseases).
– alcohol consumption;
– psychological stress.
The Global Longevity Institute pursues its mission through a wide range of activities. It carries out original researches and analysis on issues related to global aging. It publishes information, articles and presentations that communicate its findings and recommendations to the broadest possible audience.
GLI organizes and hosts conferences and forums that bring together science experts for constructive dialog about the scope of the global aging challenge and the most effective ways of the prolongation of life. Scientists and clinicians work together to identify and test dietary, pharmacological, regenerative and biotechnology, physical activity and engineering approaches to prevent multiple diseases of aging and maximize healthspan.
We are working in the synergism created by the various laboratories from 5 medical company and attracting leading scientists interested in a longevity research-centered approach to improve human health.
With anti-aging medical checkup, the GLI medical specialists will address potential threats to your health and check your aging progress, to provide you with a one-on-one custom health care program to keep you healthy.
GLI anti-aging and medical checkup programme is aimed at revitalising the entire body and suspension the ageing process.
Anti-aging and Medical Checkup includes:
The liver is the largest internal organ in the human body and its proper function is indispensable for many critical metabolic functions, including the regulation of lipid and sugar metabolism, the production of important proteins, including those involved in blood clotting, and purification of blood. There are over 100 described diseases of the liver, and because of its many functions, these can be highly debilitating and life-threatening unless effectively treated.
Liver diseases can result from injury to the liver caused by a variety of insults, including hepatitis C virus (HCV), hepatitis B virus (HBV), obesity, chronic excessive alcohol use or autoimmune diseases. Many people with active liver disease remain undiagnosed largely because liver disease patients are often asymptomatic for many years. According to the European Association for the Study of the Liver (EASL), 29 million Europeans have chronic liver disease, and liver disease represents approximately two percent of deaths annually. In studies has been shown that in obese people hepatic tissue was characterized by signs of accelerated aging.
ALT is an enzyme that is produced in liver cells and is naturally found in the blood of healthy individuals. In liver disease, liver cells are damaged and as a consequence, ALT is released into the blood, increasing ALT levels above the normal range. Physicians routinely test blood levels of ALT to monitor the health of a patient’s liver.
ALT level is a clinically important biochemical marker of the severity of liver inflammation and ongoing liver disease. Elevated levels of ALT represent general markers of liver cell death and inflammation without regard to any specific mechanism. However, in later stage cirrhosis patients, ALT levels have been shown to not be elevated above the normal range.
Aspartate aminotransferase (AST) is a second enzyme found in the blood that is produced in the liver and routinely measured by physicians along with ALT. As with ALT, AST is often elevated in liver disease and, like ALT, is considered an overall marker of liver inflammation.
Another important marker of liver cell death is a protein fragment called caspase-cleaved Cytokeratin 18 (cCK18). During apoptosis, a key structural protein within the cell called Cytokeratin 18, or CK18, is specifically cleaved by caspases, which results in the release of cCK18 into the blood stream. cCK18 is easily detected in the blood with a commercially-available test and is a mechanism-specific biomarker of apoptosis and caspase activity.
Unlike ALT, cCK18 is elevated in patients with advanced liver disease and cirrhosis. Importantly, cCK18 is also present in healthy subjects and multiple studies have demonstrated an approximate basal level in healthy subjects. Numerous independent clinical trials and published studies have demonstrated the utility of cCK18 for detecting and gauging the severity of ongoing liver disease across a variety of disease etiologies. These studies have demonstrated correlations between disease and cCK18 levels in patients with ACLF, LC, portal hypertension (PH), HCV, NASH and various other liver disease indications. For example, it has been shown that in HCV patients, the severity of liver disease was correlated with cCK18 levels and apoptosis, such that the more severe the disease, the higher the serum level of cCK18.
In ACLF patients, studies have shown that blood levels of cCK18 were higher in non-surviving patients than in patients that survived. In LC patients, studies have shown that cCK18 levels are elevated and correlate with liver inflammation and cholestasis. cCK18 is a valid and important biomarker of excessive apoptosis in liver disease.
Genetic testing provides valuable information about our health that allows us to take the correct measures to improve our health and vitality, as well as prevent potential diseases. By understanding what lifestyle habits we should adopt and what nutrition plan suits us best, we can boost our health and prevent premature aging.
What if you could find out what types of workouts are the most beneficial and effective for your body? What foods youâre intolerant to and which ones you should be including in your diet? Thanks to genetic testing, itâs possible. The future of health and fitness is hyper-personalisation through DNA tests.
Through genetic testing, we can analyse the genetic make-up of each individual and gain a better understanding of our wellness needs. Instead of settling for a generic plan that might work for one person, but not for each individual, you can have access to a fitness plan that is tailored to your DNA, improving the benefits, efficiency and endurance of each individual.
Genetic testing doesnât only provide valuable information about what the most appropriate workout plan is for each person, but also nutritional advice based on your DNA results. As a result, youâre able to create a personalised nutrition and fitness plan adapted to your needs and provide the best results for your health and wellbeing.
If you want to create a hyper-personalised health and fitness plan, than you should consider getting a DNA test to determine your bodyâs needs.
High technologies of longevity include the latest new drugs and resources that exist in the world practice for prolonging life.
The rejuvenation program includes only natural products, anti-oxidants, senolytics, polyvitamins, minerals, aminoacids and chelating agents. No secondary effects. These treatments have been created and patented by Dr Elina Manzhalii.
GLI helps you to live healthier and beautiful lifestyle by slowing down the aging process. We recommend high technologies of longevity to people with fatigue, sleep disorder, stress, and hormone syndrome and for prevention of deseases.
Depending on the blood results and the anamnesis of the patient, this treatment can be adapted and focused on specific health problem.
The organizationâs vision is to holistically manage wellness, nutrition and health, and to diagnose and treat diseases to significantly change the treatment paradigm for patients by using personalized medicine and cutting edge technologies.
Potentially interested parties should note that participation in the Global Longevity project is subject to limitations imposed by applicable securities laws in various jurisdictions.
Potential investors should note that participation in the Global Longevity Sale is subject to limitations imposed by applicable securities laws in various jurisdictions. The following does neither constitute an offer to buy or to subscribe for the Potentially interested parties should note that participation in the Global Longevity project is subject to limitations imposed by applicable securities laws in various jurisdictions.
Potential investors should note that participation in the Global Longevity project Sale is subject to limitations imposed by applicable securities laws in various jurisdictions. The following does neither constitute an offer to buy or to subscribe for the Global Longevity project. Investors should make their decision to buy or to subscribe to Global Longevity project.
Investors are furthermore advised to consult their bank or financial adviser before making any investment decision. This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements.
Against the background of these uncertainties, readers should not rely on forward-looking statements. Global Longevity project assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.
The Global Longevity project are not for sale and distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan, Australia, North Korea, Iran, Myanmar, Afghanistan, Angola, Aruba, Bangladesh, Belarus, Benin, Bhutan, Bolivia, Botswana, Brunei Darussalam, Burkina Faso, Bosnia, Burundi, Cambodia, Cameroon, Cape Verde, Central Africa republic, Chad, Comorros, Congo, Congo Democratic republic, Cuba, Cote d’Ivoire, Djibouti, Dominica, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, Guyana, Guinea, Guinea Bissau, Haiti, Honduras, Iraq, Jordan, Kenya, Kyrgyz Republic, Laos People’s Republic, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Micronesia, Moldova, Mongolia, Mozambique, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palestinian Areas, Papua New Guinea, Reunion, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Georgia, Sudan, Sri Lanka, Suriname, Syria, Swaziland, Tajikistan, Tanzania, Timor, Togo, Tonga, Tunisia, Turkmenistan, Uganda, Uzbekistan, Venezuela, Western Sahara, Yemen, Zambia, Zimbabwe or any jurisdiction into which the same would be unlawful.
This announcement does not constitute or form a part of any offer or solicitation to purchase, subscribe for or otherwise acquire securities in the United States, Canada, Japan, Australia, North Korea, Iran, Myanmar,Afghanistan, Angola, Aruba, Bangladesh, Belarus, Benin, Bhutan, Bolivia, Botswana, Brunei Darussalam, Burkina Faso, Bosnia, Burundi, Cambodia, Cameroon, Cape Verde,Central Africa republic, Chad, Comorros, Congo, Congo Democratic republic, Cuba, Cote d’Ivoire, Djibouti, Dominica, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, Guyana, Guinea, Guinea Bissau, Haiti, Honduras, Iraq, Jordan, Kenya, Kyrgyz Republic, Laos People’s Republic, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Micronesia, Moldova, Mongolia, Mozambique, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palestinian Areas, Papua New Guinea, Reunion, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Georgia, Sudan, Sri Lanka, Suriname, Syria, Swaziland, Tajikistan, Tanzania, Timor, Togo, Tonga, Tunisia, Turkmenistan, Uganda, Uzbekistan, Venezuela, Western Sahara, Yemen, Zambia, Zimbabwe or any jurisdiction in which such an offer or solicitation is unlawful.
The Global Longevity project will not be registered under the US Securities Act of 1933, as amended or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States.
The Global Longevity project have not been approved or disapproved by the US Securities and Exchange Commission, any state’s securities commission in the United States or any US regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Global Longevity project or the accuracy or adequacy of this announcement. Any representation to the contrary is a criminal offence in the United States. The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom.
This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Global Longevity project are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such the Global Longevity project will be engaged in only with, relevant persons.
Any person who is not a relevant person should not act or rely on this document or any of its contents. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.